Table 2.
Summary table of all Monkeypox cases highlighting demographic, symptoms, management, and outcomes
| Variables | n/N (%) |
|---|---|
| N | 1078 |
| Age (mean, SD) | 20.66 ± 16.45 years |
| Male, n (%) | 583 (54%) |
| Female, n (%) | 489 (46%) |
| NR | 6 |
| Country | |
| United Kingdom | 2/10 (20%) |
| Nigeria | 1/10 (10%) |
| Sierra Leone | 1/10 (10%) |
| Democratic Republic of the Congo | 3/10 (30%) |
| Singapore | 1/10 (10%) |
| United States | 1/10 (10%) |
| Australia | 1/10 (10%) |
| Monkeypox viral DNA test | RT‐PCR: 1074/1075 (99.9%) |
| Symptoms | |
| Fever | 1037/1075 (96%) |
| Headache | 1015/1068 (95%) |
| Lymphadenopathy |
905/1070 (85%) (Cervical lymphadenopathy is most common) |
| Upper respiratory symptoms | 1026/1060 (97%) |
| Rash | 1078/1078 (100%) |
| Oral ulcers | 1018/1057 (96%) |
| Vomiting | 1011/1059 (95%) |
| Conjunctivitis | 1017/1058 (96%) |
| Management | |
| Antivirals | 7/11 (63%) |
| Antibiotics | 4/10 (40%) |
| Length of hospitalization (mean) | 13.3 ± 6.37 days |
| Duration of management (mean) | 5 days |
| Outcomes | Recovery: 19/20 (95%), Death: 1/20 (5%) |